The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome

Familial Cancer

Volumn 13, Issue 1, 2014, Pages 127-130

  Renaux Petel, Mariette ^a,b   Sesboüé, Richard ^a   Baert Desurmont, Stéphanie ^a,b   Vasseur, Stéphanie ^b   Fourneaux, Steeve ^b   Bessenay, Emilie ^b   Frébourg, Thierry ^a,b   Bougeard, Gaëlle ^a  

^a UNIVERSITY OF ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Li Fraumeni syndrome; MDM2; Modifier genes; TP53

Indexed keywords

PROTEIN MDM2; MDM2 PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADRENAL CORTEX CARCINOMA; ADULT; ALLELE; ARTICLE; BRAIN TUMOR; EXON; FAMILIAL CANCER; FEMALE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; ONSET AGE; OSTEOSARCOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; GENETICS; GERMLINE MUTATION; LI-FRAUMENI SYNDROME;

ADULT; AGE OF ONSET; FEMALE; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; LI-FRAUMENI SYNDROME; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896698504     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9667-2     Document Type: Article

References (16)

1. Malkin D (2011) Li-Fraumeni syndrome. Genes Cancer 2: 475-484
2. Chompret A, Abel A, Stoppa-Lyonnet D, Brugières L, Pagès S, Feunteun J, Bonaïti-Pellié C (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43-47 (Pubitemid 32102322)
3. Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaïti-Pellié C, Frébourg T, French LFS Working Group (2008) Molecular basis of the Li Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535-538
4. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti- Pellié C, Stoppa-Lyonnet D, Frébourg T (2009) 2009 Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27:e108-e109
5. Zerdoumi Y, Aury-Landas J, Bonaïti-Pellié C, Derambure C, Sesboüé R, Renaux-Petel M, Frebourg T, Bougeard G, Flaman JM (2013) Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum Mutat 34:453-461
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602 (Pubitemid 39535748)
7. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugières L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellié C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531-533 (Pubitemid 43927330)
8. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15:110-114 (Pubitemid 44921674)
9. Marcel V, Palmero EI, Falagan-Lotsch P, Martel-Planche G, Ashton-Prolla P, Olivier M, Brentani RR, Hainaut P, Achatz MI (2009) TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 46:766-772
10. Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC (2011) Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 129:663-673
11. Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Munro AJ, Baker L, Purdie CA, Lane DP, Thompson AM (2008) MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8:281
12. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS, Stoltenberg C, Romundstad P, Hveem K, Lillehaug JR, Vatten L, Devilee P, Dørum A, Lønning PE (2011) The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 19:273-282
13. Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL (2008) An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One 3:e1951
14. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, MoMaTEC Study Group, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lønning PE (2012) SNP285C modulates oestrogen receptor/Sp1binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer 48:1988-1996
15. Castéra L, Sabbagh A, Dehainault C, Michaux D, Mansuet-Lupo A, Patillon B, Lamar E, Aerts I, Lumbroso-Le Rouic L, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C (2010) MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 102:1805-1808
16. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N, Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2007) RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186-1200